Rauwolscine hydrochloride

Discontinued Product

Rauwolscine hydrochloride (Cat. No. 0891) has been withdrawn from sale for commercial reasons.
Description: α2 antagonist
Alternative Names: α-Yohimbine hydrochloride, Corynanthidine
Chemical Name: 17α-Hydroxy-20α-yohimban-16β-carboxylic acid,methyl ester hydrochloride
Purity: ≥95% (HPLC)
Citations (2)
Literature (2)

Biological Activity for Rauwolscine hydrochloride

Rauwolscine hydrochloride is a standard α2-adrenergic antagonist (Ki values are 3.5, 4.6, and 0.6 nM at cloned human α2A, α2B, and α2C-adrenoceptors respectively). Partial agonist at 5-HT1A receptors.

Diastereomer also avilable.

Technical Data for Rauwolscine hydrochloride

M. Wt 390.91
Formula C21H26N2O3.HCl
Storage Store at RT
Purity ≥95% (HPLC)
CAS Number 6211-32-1
PubChem ID 197067
Smiles [H][C@]12C4=C(C(C=CC=C5)=C5N4)CCN1C[C@]3([H])[C@]([C@H]([C@](OC)=O)[C@@H](O)CC3)([H])C2.Cl

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

Tocris products are intended for laboratory research use only, unless stated otherwise.

Product Datasheets for Rauwolscine hydrochloride

Certificate of Analysis / Product Datasheet
Select another batch:

References for Rauwolscine hydrochloride

References are publications that support the biological activity of the product.

Arthur et al (1993) Partial agonist properties of rauwolscine and yohimbine for the inhibition of adenylyl cyclase by recombinant human 5-HT1A receptors. Biochem.Pharmacol. 45 2337 PMID: 8517875

Hieble et al (1995) β- and γ-Adrenoceptors: from the gene to the clinic. 1. Molecular biology and adrenoceptor subclassification. J.Med.Chem. 38 3415 PMID: 7658428

Uhlen et al (1998) [3H]RS79948-197 binding to human, rat, guinea pig and pig α2A-, α2B-, and α2C-adrenoceptors. Comparison with MK912, RX821002, rauwolscine and yohimbine. Eur.J.Pharmacol. 343 93 PMID: 9551719

View Related Products by Target

View Related Products by Product Action

View all Adrenergic α2 Receptor Antagonists

Keywords: Rauwolscine hydrochloride, Rauwolscine hydrochloride supplier, α2-adrenoceptor, alpha2-adrenoceptor, antagonists, α2-Adrenergic, alpha2-Adrenergic, a2-adrenoceptor, a2-adrenergic, Receptors, alpha-Yohimbine, hydrochloride, a-Yohimbine, Corynanthidine, Adrenergic, Alpha-2, 0891, Tocris Bioscience

2 Citations for Rauwolscine hydrochloride

Citations are publications that use Tocris products. Selected citations for Rauwolscine hydrochloride include:

Cardin and Schmidt (2004) Noradrenergic inputs mediate state dependence of auditory responses in the avian song system. J Neurosci 24 7745 PMID: 15342742

Moura et al (2006) Alpha2-adrenoceptor subtypes involved in the regulation of catecholamine release from the adrenal medulla of mice. Br J Pharmacol 149 1049 PMID: 17075569

Reviews for Rauwolscine hydrochloride

There are currently no reviews for this product. Be the first to review Rauwolscine hydrochloride and earn rewards!

Have you used Rauwolscine hydrochloride?

Submit a review and receive an Amazon gift card.

$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image

$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image

$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image

Submit a Review

Literature in this Area

Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!

*Please note that Tocris will only send literature to established scientific business / institute addresses.

Depression Poster

Depression Poster

Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.

Parkinson's Disease Poster

Parkinson's Disease Poster

Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.